Skip to the answer

Berotralstat Uses, Dosage, Side Effects and Interactions

Brand name
Orladeyo

Orladeyo was approved by the FDA in December 2020. No generic is listed as oral pellets and capsules.

First generic of Orladeyo: our estimate, October 2035

Berotralstat is a once-daily oral medicine that helps prevent attacks of hereditary angioedema (HAE) in adults and children 2 years and older. It does not treat attacks once they start.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 21, 2026 Content updated Nov 19, 2026 Where our facts come from

Quick links

Ask Anything About BerotralstatType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Berotralstat in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Berotralstat (Orladeyo) prevents attacks of hereditary angioedema (HAE) by blocking plasma kallikrein, which keeps bradykinin, the substance that makes blood vessels leak and swell, in check; it was the first once-daily option by mouth for HAE prevention, is still fairly new, and is not available as a generic. Most people tolerate it well, and the side effects they notice are mostly stomach-related (belly pain, diarrhea, vomiting, heartburn), often early on. The thing to respect is the dose, because it will not stop an attack already underway and extra doses can lengthen the QTc interval, a measure of the heart's electrical cycle.

Key Takeaways From the HelloPharmacist Team

  • Take it once a day with food, as a capsule for ages 12 and up or as weight-based oral pellets for younger children.
  • Keep your rescue medicine for acute attacks with you and follow your HAE action plan, since berotralstat only lowers how often attacks happen.
  • Never double up to make up for a missed dose, and get medical help if you take more than your prescribed daily amount.
  • Run every new prescription, over-the-counter or herbal product past your pharmacist, because berotralstat raises levels of many medicines and some drugs weaken it.

How we write and review this content: our editorial policy

Berotralstat by the Numbers

Strengths
7
across 2 forms
Makers and packagers
1
Earliest FDA record
2018
Rank by Medicaid prescriptions
#1,332 of 1,682 drugs
More prescriptions than 20% of the 1,682 drugs we measure
980 prescriptions, Q1–Q4 2025

Patient Information Guide for Berotralstat

What It’s Used For

Berotralstat is used to prevent attacks of hereditary angioedema (HAE).

  • Orladeyo is approved to prevent HAE attacks in adults and children 2 years and older.
  • Orladeyo capsules are for those 12 and older.
  • Orladeyo oral pellets are for children 2 to under 12 years.
  • It is not for treating acute HAE attacks.

How It Works

Berotralstat is a plasma kallikrein inhibitor. It blocks plasma kallikrein, a protein that helps make bradykinin. Bradykinin widens blood vessels and makes them leaky, causing the swelling and pain of HAE.

In people with HAE due to C1-inhibitor deficiency or dysfunction, plasma kallikrein is not properly regulated. Berotralstat reduces its activity to help control extra bradykinin.

Drug Class

Drug Class

  • Plasma Kallikrein Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Plasma Kallikrein Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Cytochrome P450 2D6 Inhibitors
  • Cytochrome P450 3A4 Inhibitors
  • Kallikrein Inhibitors
  • P-Glycoprotein Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Berotralstat in the FDA’s index.

From our Patient Information GuideBerotralstat is a plasma kallikrein inhibitor. It blocks plasma kallikrein, a protein that helps make bradykinin. Bradykinin widens blood vessels and makes them leaky, causing the swelling and pain of HAE. Read How Berotralstat Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Berotralstat in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Drugs used in hereditary angioedema

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Orladeyo is taken by mouth once a day with food.

  • Adults and children 12 and older take capsules.
  • Children 2 to under 12 take oral pellets, dosed by body weight.
  • Some people with liver problems or persistent stomach side effects may be given a lower capsule dose.

Follow your prescriber's directions and the label. Do not take extra doses.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Preventing attacks of hereditary angioedema (HAE)

Adults and children 12 years old and older Usual dose 150 mg once a day
  • 150 mg orally once daily with food

Good to know

Higher than the prescribed once-daily dose is not recommended

Adults and children 12 and older · 110 mg Usual dose 110 mg once a day
  • 110 mg taken orally once daily with food

Good to know

Mild hepatic impairment (Child-Pugh Class A): no dosage modification

Adults and children 12 and older · Persistent GI adverse reactions Usual dose 110 mg once a day
  • Consider a lower dosage of 110 mg once daily with food

Good to know

For ages 2 to less than 12 years, consider risks and benefits of continuing treatment

Children 2 to less than 12 years old, 12 kg to less than 24 kg Usual dose 72 mg once a day

Good to know

Take with food; a meal just before or after dosing

Children 2 to less than 12 years old, 24 kg to less than 32 kg Usual dose 96 mg once a day

Good to know

Take with food; a meal just before or after dosing

Children 2 to less than 12 years old, 32 kg to less than 40 kg Usual dose 108 mg once a day

Good to know

Take with food; a meal just before or after dosing

Children 2 to less than 12 years old, 40 kg or greater Usual dose 132 mg once a day

Good to know

Take with food; a meal just before or after dosing

See the Full Dosing Instructions on DailyMed →

Side Effects

Stomach-related effects are the most common.

Common side effects

  • Stomach (abdominal) pain
  • Vomiting
  • Diarrhea
  • Back pain
  • Heartburn or acid reflux (gastroesophageal reflux disease)
  • Headache
  • Fatigue
  • Gas (flatulence)

When to get medical help

  • Call your doctor if stomach upset, vomiting or diarrhea keeps going. A lower dose may be an option for some people.
  • Get medical help if you took more than your prescribed daily dose. Higher doses can affect the heart's electrical rhythm (QTc prolongation).
  • Tell your doctor about a new skin rash. Rash was rare in studies and went away, even in people who kept taking the medicine.
  • Do not use it to treat an attack in progress. Follow your HAE action plan and call your doctor.

Stomach effects usually appeared early, became less frequent over time and typically went away on their own. Nausea has also been reported after approval. Contact your doctor if symptoms persist or you develop a rash.

Warnings and Precautions

The biggest warning is QTc interval prolongation (a change in the heart's electrical rhythm) at higher-than-recommended doses. Do not take extra doses or more than prescribed.

Orladeyo should not be used to treat acute HAE attacks. In studies, one person stopped treatment because of elevated liver enzymes found on lab tests.

Interactions

Orladeyo can interact with several types of medicines.

  • P-gp inducers: can lower Orladeyo levels and make it less effective, so avoid them.
  • CYP2D6 or CYP3A4 substrates: Orladeyo can raise their levels.
  • P-gp substrates: Orladeyo can raise their levels.
  • Desogestrel: levels of its active form can rise.

Interactions Listed in the FDA-Approved Label

From the Berotralstat prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • P-gp inducers
    What happensP-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO.
    What to doAvoid concomitant use.
  • CYP2D6 and CYP3A4 substrates
    What happensORLADEYO 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4 and can increase exposure to these substrates, raising the risk of their adverse reactions.
    What to doWhere minimal increases may lead to serious adverse reactions, closely monitor or modify the substrate dosage.
  • Desogestrel
    What happensORLADEYO increases exposure to etonogestrel, the active metabolite of desogestrel, and may increase the risk of desogestrel-associated adverse reactions.
    What to doConsider the benefits and risks when using together.
  • P-gp substrates
    What happensORLADEYO at 2-times the maximum recommended dose of 150 mg is a P-gp inhibitor and can increase exposure of P-gp substrates, raising the risk of their adverse reactions.
    What to doHigher-than-recommended dosages are not recommended; where minimal increases may lead to serious adverse reactions, closely monitor or modify the substrate dosage.
Read the label’s full interactions text

7 DRUG INTERACTIONS P-gp inducers: Avoid use with ORLADEYO. CYP2D6, CYP3A4 or P-gp Substrates: When used concomitantly with ORLADEYO, closely monitor or modify the dosage of the substrates where minimal increases in concentration may lead to serious adverse reactions. 7.1 Effect of Other Drugs on ORLADEYO P-gp Inducers Berotralstat is a substrate of P-gp and BCRP. P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant use of P-gp inducers with ORLADEYO. 7.2 Effect of ORLADEYO on Other Drugs CYP2D6 and CYP3A4 Substrates ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. Concomitant use of ORLADEYO with CYP2D6 or CYP3A4 substrates can increase exposure of the CYP2D6 or CYP3A4 substrates and may increase the risk of adverse reactions associated with the substrates. If ORLADEYO is concomitantly used with CYP2D6 or CYP3A4 substrates where minimal increases in the concentration of the substrates may lead to serious adverse reactions, closely monitor or modify the dosage of the CYP2D6 or CYP3A4 substrate. Refer to the Prescribing Information of the CYP2D6 or CYP3A4 substrate. Desogestrel Concomitant use of ORLADEYO with desogestrel increases exposure to etonogestrel, the active metabolite of desogestrel, and may increase the risk of desogestrel-associated adverse reactions. Consider the benefits and risks when using ORLADEYO concomitantly with desogestrel. P-gp Substrates ORLADEYO at 2-times the maximum recommended dose of 150 mg is a P-gp inhibitor and can increase exposure of P-gp substrates, leading to increased risk of adverse reactions associated with the substrates. Higher-than-recommended dosages of ORLADEYO are not recommended.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • No contraindications are listed.
  • Liver impairment: moderate or severe may need a lower capsule dose; children 2 to under 12 should avoid it.
  • Kidney impairment: children 2 to under 12 with severe impairment should avoid it. It is not recommended in end-stage renal disease.
  • Pregnancy: data are insufficient to know the risks.
  • Breastfeeding: not known whether it passes into milk.
  • Not established under 2 years of age.
  • Older adults: no overall differences were seen.

Half-Life and How Your Body Processes It

After a dose, levels peak in about 5 hours when taken with food. Food did not meaningfully change how much drug was absorbed, but it delayed the peak. Capsules and pellets gave no clinically significant difference in exposure in adults. It reaches steady state in about 6 to 12 days. Its half-life is about 93 hours. It is broken down by CYP2D6 and CYP3A4 and mostly leaves the body in feces.

Storage

Store at 20°C to 25°C (68°F to 77°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Berotralstat: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Berotralstat — the kind of thing our pharmacy team would talk through with you at the counter.

What is berotralstat used for?

It helps prevent attacks of hereditary angioedema (HAE), a condition that causes episodes of swelling and pain. It is for adults and children 2 and older. It is not meant to treat an attack once it has started.

How do I take berotralstat?

Take it by mouth once daily with food. Adults and kids 12 and older take capsules. Younger kids take pellets by weight, poured in the mouth or sprinkled on soft, non-acidic food like pudding. Follow your prescriber's directions.

What if I take more than my prescribed dose of berotralstat?

Don't take extra doses. Doses above the recommended amount can affect your heart's rhythm (QTc prolongation). If you took more than prescribed, contact your doctor or pharmacist right away.

What side effects should I expect?

Stomach problems are the most common: belly pain, vomiting, diarrhea and reflux. Back pain, headache and fatigue also occur. Stomach symptoms usually show up early and ease over time. If they persist, call your doctor, since a lower dose may help.

Can I take other medicines with berotralstat?

Some medicines can clash with it. P-gp inducers can make it work less well, and it can raise levels of drugs handled by CYP2D6, CYP3A4 or P-gp. It can also raise levels of the active form of desogestrel. Always check with me before starting anything new.

Is berotralstat safe in pregnancy or while breastfeeding?

There is not enough data in pregnant women to know the risks. It is also unknown whether it passes into breast milk. Talk with your doctor about the benefits and risks for you.

Is berotralstat available over the counter?

No. Berotralstat is a prescription medicine: every berotralstat product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was berotralstat first available?

The earliest FDA record we hold for berotralstat is from 2018: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when berotralstat was first used.

What is the brand name of berotralstat?

Berotralstat is the generic name. Its brand name is Orladeyo.

What is the generic name of Orladeyo?

The generic name of Orladeyo is berotralstat. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is berotralstat?

Berotralstat belongs to the drug class Plasma Kallikrein Inhibitor, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: CYP2D6 Enzyme Inhibitor, CYP3A4 Enzyme Inhibitor and P-glycoprotein Inhibitor.

What strengths does berotralstat come in?

Berotralstat is listed in the FDA's National Drug Code Directory in these forms and strengths. Oral pellets (by mouth): 72 mg, 96 mg, 108 mg, 132 mg and 150 mg. Capsule (by mouth): 110 mg and 150 mg. A listing does not mean every pharmacy stocks every strength.

How much does berotralstat cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, state Medicaid programs paid an average of $1,584.29 to $1,642.69 per capsule of brand-name Orladeyo across 2 strengths over the four quarters through Q1 2026 (CMS's State Drug Utilization Data), before the rebates drug makers pay Medicaid. CMS's weekly pharmacy survey (NADAC) has no price for it, and Medicaid's figure is what a program paid, not the price at the counter. No national price was found for berotralstat oral pellets. The pharmacy prices section of this page lists every strength priced.

Is there a berotralstat shortage?

No. Berotralstat is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the berotralstat prescribing information (package insert)?

The full FDA-approved prescribing information for berotralstat, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from BioCryst Pharmaceuticals Inc.'s, revised Oct 23, 2026, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Berotralstat

Skip the scrolling. Ask in your own words and get an answer from Berotralstat’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Berotralstat’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Berotralstat on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Berotralstat Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Berotralstat Forms and Strengths (How It Comes)

Berotralstat comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Berotralstat inactive ingredients by manufacturer.

Oral pellets

By mouth
Brands Orladeyo (2020)
How this form is used
What it may be used for
  • Orladeyo oral pellets are used to prevent HAE attacks in children 2 to under 12 years, with dosing based on body weight.
Important instructions
  • Orladeyo pellets: pour a packet directly into the mouth and swallow right away with water or milk, or sprinkle over about a tablespoon of soft, non-acidic food.
  • Orladeyo pellets should not be chewed or crushed, which causes a bitter taste.
  • Orladeyo pellets: avoid acidic foods such as yogurt and applesauce. Throw away pellets not eaten within 10 minutes of sprinkling.
  • Orladeyo pellets: have a meal just before or after the dose.
Available strengths 5 strengths
5 FDA-listed product records ⓘ

Capsule

By mouth
Brands Orladeyo (2020)
How this form is used
What it may be used for
  • Orladeyo capsules are used to prevent HAE attacks in adults and children 12 years and older.
Important instructions
  • Orladeyo capsules are taken by mouth once daily with food.
  • Orladeyo capsules are the form used if a lower dose is needed, such as for moderate or severe liver impairment or ongoing stomach side effects in people 12 and older.
Available strengths 2 strengths
2 FDA-listed product records ⓘ

Berotralstat on the U.S. Market: Products, Makers and Brands

How Berotralstat appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 7 Berotralstat product records with the FDA, mostly as oral pellets, capsule; the earliest marketing or approval year on record is 2018. The one brand name in the directory today is Orladeyo; the rest are generics.

2
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
7
FDA-listed product records ⓘ
2018
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (4) · Unfinished capsule (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

How Widely Berotralstat Is Used (Medicaid Data)

How many Berotralstat prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

980
Medicaid prescriptions filled (Q1–Q4 2025)
$43.2M paid by Medicaid, before rebates

How commonly is Berotralstat prescribed? Of the 1,682 medications we measure, Berotralstat ranks #1,332 by Medicaid prescriptions — more than 21% of them.

Where Berotralstat ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Berotralstat product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 150 mg oral capsule is the most-dispensed Berotralstat product — about 98% of these Medicaid prescriptions.

berotralstat 150 MG Oral Capsule Most dispensed

964 Medicaid prescriptions (Q1–Q4 2025) 98% of Berotralstat prescriptions shown $42.5M paid by Medicaid, before rebates ≈ $44,093 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2467565

berotralstat 110 MG Oral Capsule

16 Medicaid prescriptions (Q1–Q4 2025) 2% of Berotralstat prescriptions shown $711,897 paid by Medicaid, before rebates ≈ $44,494 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2467573

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 5 listed Berotralstat NDCs had Medicaid claims.

Compare Berotralstat Products

A representative set of FDA-listed product records for Berotralstat — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Capsule
110 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
150 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
💊Oral pellets
72 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
96 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
108 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
132 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →
150 mg Oral BioCryst Pharmaceuticals Inc. NDA View NDC →

Showing 7 of 7 products — FDA National Drug Code Directory. See every product, package size and price: browse all 7 Berotralstat NDCs →

Berotralstat Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Berotralstat recalls since July 2021.

✅No Berotralstat recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Berotralstat in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
2
Strengths
6
Forms in current FDA listings
2 of 2
In current FDA listings No current FDA listing
Ingredient (IN) Berotralstat RxCUI 2467540
  1. Dose form (SCDF) Oral Capsule RxCUI 2467564
    In current FDA listings
    Its 2 strengths (SCD)
  2. Dose form (SCDF) Oral Pellet RxCUI 2728873
    In current FDA listings
    Its 4 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Medicaid Pays for Berotralstat

CMS’s weekly pharmacy survey (NADAC) has no price for Berotralstat, so here is what state Medicaid programs paid for it over the four quarters through Q1 2026, before rebates. It is not your price at the counter.

No price was found for Berotralstat oral pellets, so the prices below are for the capsules only.

FormStrengthVersion What Medicaid paid
Capsule · Oral 110 mg Orladeyo (brand) $1,642.69 per capsule NDC details & Medicaid use
Capsule · Oral 150 mg Orladeyo (brand) $1,584.29 per capsule NDC details & Medicaid use
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS State Drug Utilization Data, total paid divided by units paid for across every state, for each strength’s packages.

Berotralstat Brand Names

Berotralstat has one brand name on record: Orladeyo. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Orladeyo 2020

Who Makes Berotralstat: Manufacturers and Labelers

One company lists Berotralstat products with the FDA. By number of product records, the largest are BioCryst Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

BioCryst Pharmaceuticals, Inc. 7

Sources for This Berotralstat Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Oct 23, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Berotralstat.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Finished products in the current FDA directory
7
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
BioCryst Pharmaceuticals Inc.
Linked label effective
Oct 23, 2026
Composite sections available
21
Linked SPL Set ID
3527ece1-e7e0-40b1-b0c5-6baeb0deabeb
Linked SPL Document ID
0d739120-e251-49bc-ad25-10f587ac45e1
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. BioCryst Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →